PTO/SB/08A (07-05)
Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE

Substitute for form 1449/PTO

Sheet 1

## STATEMENT BY APPLICANT (Use as many sheets as necessary)

12

Complete if Known			
Application Number	10/562,951		
Filing Date	December 23, 2005	-	
First Named Inventor	Brian Anderton, et al.		
Art Unit	Unit Not yet assigned		
Examiner Name	Not yet assigned		
Attorney Docket Number	ket Number 0380-P03923US0		

				DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2 (f known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	<sup>US-</sup> 6,057,117	05-02-2000	Stephen D. Harrison et al.	
		US-			
		US-			
	-	US-			
		US-			
		US-			
	-	US-			
		US-			
	_	US-			
		US-			
	$\vdash$	US-			
		US-			
	$\vdash$	US-			
		US-			
		US-			
		US-	1		
		US-			
		US-			1
	<del>                                     </del>	US-			

		FORE	IGN PATENT DOCU	MENTS		
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	Г
		Country Code <sup>3</sup> "Number <sup>4</sup> "Kind Code <sup>5</sup> (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T
	B1	WO 95/19178	07-20-1995			
						L
						L
					ļ	H
						L
			1			

Examiner	Date	
Signature	Considered	

"EXAMINER: Initial if reference considered, whether or not classon is in conformance with MPEP 609. Draw line through classon if not in conformance and not considered include copy of this form with next communication to applicant. "Applicant's unique setation designation number (colorisa)." See Kinds Codes of USPTO Plants Drawman size applicant, or 1970 1971 of the No-letter code (IVI) and ST. "In the No-letter cod

This collection or information is required by 37 CFR 197 and 198. The information is required to obtain or retain a benefit by he public which is to file (and by the USPTO be process) an application. Condendiality is oper

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2

PTO/SB/08B (07-05) Approved for use through 07/31/2006. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons Substitute for form 1449/PTO	e required to respond to a collection of information unless it contains a valid OMB control number.  Complete if Known		
Substitute for form 1443/170	Application Number	10/562,951	
INFORMATION DISCLOSURE	Filing Date	December 23, 2005	
STATEMENT BY APPLICANT	First Named Inventor	Brian Anderton, et al.	
(Use as many sheets as necessary)	Art Unit	Not yet assigned	
(Use as many sneets as necessary)	Examiner Name	Not yet assigned	
Sheet 2 of 2	Attorney Docket Number	0380-P03923US0	

Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Cite No. <sup>1</sup>	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
C1	MEIJER, L. et al., "Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent," Chemistry and Biology, 7:51-63, (2000)	
C2	KURET, J. et al., "Casein Kinase 1 is Tightly Associated with Paired-Helical Filaments Isolated from Alzheimer's Disease Brain," J. of Neurochemistry, 69:2506-2515, (1997)	
СЗ	SINGH, T. et al., "Phosphorylation of tau Protein by Casein Kinase-1 Converts it to an Abnormal Alzheimer-Like State," J. of Neurochemistry, 64:1420-1423, (1995)	
C4	LEE G., et al., "Tyrosine Phosphorylation of Tau," Society for Neuroscience Abstracts, 27:1436, (2001)	
C5	TROJANOWSKI, J., "Phosphorylation of paired helical filament tau in Alzheimer's disease neurofibrillary lesions: focusing on phosphatases," Faseb J., 9:1570-1576, (1995)	
C6	LARNER, A., "Tau protein as a therapeutic target in Alzheimer's disease and other neurodegenerative disorders," Expert Opinion on Therapeutic Patents, 9:1359-1370, (1999)	
C7	CASTRO, A., et al., "Inhibition of tau phosphorylation: a new therapeutic strategy for the treatment of," Expert Opinion on Therapeutic Patents, 10:1519-1527, (2000)	
C8	SINGH, T., et al., "Non-proline-dependent protein kinases phosphorylate several sites found in tau from Alzheimer," Molecular and Cellular Biochemistry, 154:143-151, (1996)	
C9	RODER, H., "Prospect of Therapeutic Approaches to Tauopathies," J. of Molecular Neuroscience, 20:197-201, (2003)	
	C1 C2 C3 C4 C5 C6 C7 C8	number(s), publisher, city and/or country where published.  MEIJER, L. et al., "Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent," Chemistry and Biology, 7:51-63, (2000)  KURET, J. et al., "Casein Kinase 1 is Tightly Associated with Paired-Helical Filaments Isolated from Alzheimer's Disease Brain," J. of Neurochemistry, 69:2506-2515, (1997)  SINGH, T. et al., "Phosphorylation of tau Protein by Casein Kinase-1 Converts it to an Abnormal Alzheimer-Like State," J. of Neurochemistry, 64:1420-1423, (1995)  LEE G., et al., "Tyrosine Phosphorylation of Tau," Society for Neuroscience Abstracts, 27:1436, (2001)  TROJANOWSKI, J., "Phosphorylation of paired helical filament tau in Alzheimer's disease neurofibrillary lesions: focusing on phosphatases," Faseb J., 9:1570-1576, (1995)  RANNER, A., "Tau protein as a therapeutic target in Alzheimer's disease and other neurodegenerative disorders," Expert Opinion on Therapeutic Patents, 9:1359-1370, (1999)  CASTRO, A., et al., "Inhibition of tau phosphorylation: a new therapeutic strategy for the treatment of," Expert Opinion on Therapeutic Patents, 10:1519-1527, (2000)  SINGH, T., et al., "Non-proline-dependent protein kinases phosphorylate several sites found in tau from Alzheimer," Molecular and Cellular Biochemistry, 154:143-151, (1996)

Examiner	and the state of the state of	Date	09/12/2008
Signature	/David Steadman/	Considered	09/12/2008

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique classon designation number (policosa). 2 Applicant is to place a check mark here if English language Translation is statched.
This collection of Information is required by 37 CFR 13.0. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application from to file USPTO. Time will vary depending upon the individual case of the complete application from to file USPTO. Time will vary depending upon the individual case (procurents on the Trademark Office, P.O. Box. 1450, Alexandre, W. 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patients, P.O. Box. 1450, Alexandre, W. 22313-1450.